Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Non Operating Income: 2018-2025

Historic Non Operating Income for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Sep 2025 value amounting to $3.2 million.

  • Arcturus Therapeutics Holdings' Non Operating Income fell 15.30% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year decrease of 37.52%. This contributed to the annual value of $15.2 million for FY2024, which is 8.41% down from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' Non Operating Income stood at $3.2 million, which was up 25.98% from $2.6 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' Non Operating Income's 5-year high stood at $6.9 million during Q4 2023, with a 5-year trough of -$564,000 in Q1 2022.
  • For the 3-year period, Arcturus Therapeutics Holdings' Non Operating Income averaged around $3.7 million, with its median value being $3.3 million (2023).
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' Non Operating Income crashed by 2,281.82% in 2021 and then spiked by 1,340.19% in 2023.
  • Arcturus Therapeutics Holdings' Non Operating Income (Quarterly) stood at -$524,000 in 2021, then skyrocketed by 295.61% to $1.0 million in 2022, then spiked by 571.32% to $6.9 million in 2023, then slumped by 53.29% to $3.2 million in 2024, then dropped by 15.30% to $3.2 million in 2025.
  • Its Non Operating Income was $3.2 million in Q3 2025, compared to $2.6 million in Q2 2025 and $2.8 million in Q1 2025.